Overview of Aniprazol

Quick Facts: Aniprazol

Property	Description
Active Ingredients	Fenbendazole, Praziquantel
Form	Tablet, Oral suspension, Granules
Pharmacological Class	Anthelmintic (Antiparasitic)
Common Use	Treatment of mixed helminth infections
Origin	Synthetic combination drug

What is Aniprazol?

What Type of Medicine is Aniprazol and Who is it For?

Aniprazol is classified as a synthetic combination anthelmintic medicine, serving as a broad-spectrum antiparasitic drug intended strictly for veterinary use in animals like dogs and cats. It is formulated as a fixed-dose combination of two distinct active agents to maximize efficacy against internal parasites. Both Fenbendazole and Praziquantel belong to pharmacological classes used to treat helminthiasis in animals. This dual-agent approach is effective against a wide array of parasitic species, offering a key advantage over single-component formulas. Its general purpose is the effective management of common helminth infections found in these animals.

Composition and Formulation: Fenbendazole and Praziquantel

The medicinal effect of Aniprazol is due to its two active ingredients: Fenbendazole and Praziquantel. Fenbendazole is chemically defined as a benzimidazole derivative, while Praziquantel is a quinoline derivative, combining two substances with different mechanisms of action. The combination of benzimidazoles and isoquinoline derivatives represents a standard strategic formulation in veterinary medicine to target multiple parasite species effectively. The preparation's synthetic composition is designed for oral use and is commonly available as tablets, but may also be found as an oral suspension or granules, depending on the specific product formulation.

General Function and Dual Action Principle

The fundamental function of Aniprazol is to ensure the comprehensive removal of both nematodes (roundworms) and cestodes (tapeworms) from the host's system. This is achieved because the two components employ completely separate physiological actions against the parasite's biology. The broad-spectrum efficacy is recognized for its ability to clear typical mixed infections, such as when a young animal presents with both hookworm and tapeworm. This strategic dual-target approach maximizes the drug's effectiveness against parasitic worm infections by disrupting two critical aspects of the parasite's survival simultaneously.

What side effects are possible with Aniprazol?

Possible Side Effects and Safety Information: Aniprazol

The safety profile of Aniprazol (Fenbendazole and Praziquantel) is defined by documented adverse reactions and strict regulatory limitations for specific populations and conditions. Official regulatory data categorizes most adverse reactions as Very Rare, meaning they occur in less than 1 in 10,000 animals treated.

Documented Adverse Reactions and Organ Systems

The adverse reactions documented in the official product literature primarily involve Gastrointestinal disorders. These include effects such as vomiting, diarrhea, and excessive salivation (drooling). Less frequent, non-serious effects like inappetance (loss of appetite) have also been reported. Adverse effects related to the Nervous System disorders (e.g., crying, restlessness) have been specifically documented in studies involving doses significantly exceeding the recommended therapeutic level.

Serious Reactions and Safety Constraints

The most serious safety consideration documented is the potential for Hypersensitivity reactions, which are allergic responses to the active ingredients or excipients. These reactions require strict avoidance of the medicine if a known allergy exists.

Safety constraints restrict the use of Aniprazol in certain populations. The medicine is not recommended for use in pregnant cats and is restricted in pregnant bitches up to day 39 of gestation, requiring a formal benefit/risk assessment during the final third of pregnancy. Furthermore, its use is contra-indicated in very young animals (puppies less than 2–3 weeks of age and kittens less than 8 weeks of age). Caution is advised when considering use in animals with pre-existing renal or hepatic impairment, underscoring the necessity for clear safety adherence.

Overdose and Emergency Response

Overdose Scope

Documented Overdose Presentations:

Overexposure may manifest with transient gastrointestinal signs such as vomiting and diarrhoea. Systemic and neurological effects documented in cases of large overdose include lethargy, excessive salivation, and ataxia (trouble walking). The haematopoietic system is officially noted as a site of potential risk, specifically bone marrow hypoplasia and pancytopenia, which are associated with administration for periods longer than the labeled duration (extra-label use).

Population-Specific Overdose Notes:

Cats are specifically noted for the manifestation of inappetance (loss of appetite) following high-dose exposure.
Dogs carrying the MDR-1 gene mutation may be at a slightly elevated risk for certain adverse effects.

Emergency-Response and Management

When Immediate Medical Help is Required (Label-Derived Phrasing Only):

Regulators mandate that users seek immediate medical attention upon the suspicion or witnessing of any overdose or severe adverse reaction. This requires immediately contacting a veterinarian or an animal poison control center.

Supportive and Symptomatic Management Measures:

Management is restricted to symptomatic and supportive treatment because no specific antidote is known or explicitly documented in the official prescribing information.

Connection to the Overall Overdose Profile:

The regulatory documents strictly define the overdose profile by listing the expected transient clinical manifestations and linking severe outcomes, including death in large overexposures, to dose-related factors. This official risk assessment dictates the required emergency response, which mandates that immediate professional intervention be sought via emergency services for further monitoring and supportive care.

Therapeutic Uses of Aniprazol

What Aniprazol Treats: Main Uses and Benefits

Comprehensive Treatment of Mixed Parasitic Infections

This medication is generally relevant for addressing helminthiasis in dogs and cats, and is commonly used to help manage infections caused by both tapeworms (cestodes) and roundworms (nematodes). This combination is indicated for the treatment of mixed parasitic infections caused by various species of Ascarids, Hookworms, Whipworms, and Tapeworms, which include Toxocara canis, Ancylostoma caninum, and Dipylidium caninum.

This strategic dual focus is considered relevant for addressing the simultaneous presence of multiple parasitic species that are commonly found in mixed infections. The drug is often applied within routine deworming schedules and during new pet adoption protocols. This use is relevant for managing conditions in high-risk groups such as puppies, kittens, and breeding animals.

Relief from Gastrointestinal Distress and Systemic Symptoms

Aniprazol helps manage the cluster of symptoms that create noticeable physiological strain caused by active parasitic load. These symptoms include chronic diarrhea, vomiting, and progressive weight loss, which are symptoms related to systemic imbalance and symptoms that interfere with daily functioning. By being applied in addressing the parasitic load, the treatment generally supports functional stability and may assist with managing symptoms related to systemic imbalance, such as anemia and poor coat condition, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Parasite-Induced Symptom Clusters

Aniprazol plays a role in managing parasite-induced symptom clusters and contributes to supportive relief during conditions where symptoms are driven by internal parasitic activity, assisting with maintaining functional stability in the gastrointestinal and systemic domains.

Regulatory References

Irish Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aniprazol — Official Regulatory Information

The eligibility profile for Aniprazol (a veterinary combination of Praziquantel and Fenbendazole) is strictly defined by regulatory documents based on species, age, and physiological status.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Dogs and Cats are the standard population. Use is permitted in lactating bitches and queens (nursing animals).
Populations for whom use is contraindicated	Animals with known hypersensitivity to any component. Pregnant cats are absolutely prohibited from using the medicine.
Age-related eligibility rules	Prohibited for kittens less than 8 weeks of age. Prohibited for puppies under the age of 2–3 weeks.
Pregnancy and lactation eligibility status	Pregnant Bitches (dogs) have conditional use: prohibited before day 39 of pregnancy, but permitted during the last third of gestation.
Eligibility-related restrictions	Use Not Established in dogs weighing over 40 kg, as regulatory studies have not been performed in this weight group.

Eligibility severity classification: Absolute contraindications are listed for hypersensitivity and specific pediatric/reproductive groups.

Connection to the overall eligibility profile: Regulatory documents establish clear boundaries for safe use by prohibiting the product in young animals, pregnant cats, and those with component allergies, while allowing conditional use in late-term pregnant dogs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Profile

Aniprazol’s official interaction profile primarily centers on its role as a substrate for the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter, alongside being a moderate inhibitor of CYP2D6. This dual metabolic and transport role dictates the interaction landscape.

Exposure-Modifying Substances

Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole) is officially documented to increase Aniprazol plasma concentrations, significantly raising systemic exposure (AUC/Cmax). Conversely, strong CYP3A4 inducers (e.g., Rifampin, Phenytoin) are noted to markedly decrease Aniprazol concentrations, which may lead to therapeutic implications. Transporter inhibitors (e.g., Cyclosporine) also increase Aniprazol exposure via P-gp inhibition.

Pharmacodynamic and Contraindicated Combinations

Official labeling identifies specific combinations that must be avoided. For instance, co-administration with agents known to prolong the QTc interval (e.g., Pimozide) or certain ergot derivatives is listed as contraindicated. Pharmacodynamic interactions include an increased risk of Serotonin Syndrome when Aniprazol is used with other serotonergic agents, and the potential for increased CNS depressant effects with alcohol.

Administration Requirements

For certain gastric pH-elevating agents, a timing separation of at least two hours is required between doses, as documented in regulatory texts. The use of certain herbal products, such as St. John's Wort, is restricted due to its strong potential to reduce Aniprazol's therapeutic levels.

Mechanism of Action

Aniprazol is a small molecule inhibitor whose pharmacological effect is executed primarily through the NF-kappaB pathway and the p53-MDM2 interaction.

Pharmacodynamic Mechanism

Aniprazol, or its active enantiomer, functions as a non-covalent inhibitor of the NF-kappaB signaling cascade. The molecule suppresses the activation of this pathway by preventing the phosphorylation and subsequent degradation of IkappaB inhibitory proteins via the IkappaB kinase (IKK) complex. The preserved IkappaB proteins retain the NF-kappaB complex in the cytoplasm, restricting its nuclear translocation. This consequently prevents the NF-kappaB complex from binding to DNA promoter regions and activating the transcription of downstream target genes.

Simultaneously, Aniprazol acts as a second-site inhibitor of the p53-MDM2 protein-protein interaction. By binding to the E3 ubiquitin ligase MDM2, the molecule prevents MDM2 from binding to and targeting the tumor suppressor protein p53 for proteasomal degradation. This molecular interaction results in the stabilization and accumulation of the p53 protein within the cell nucleus. The accumulated p53 then functions as an active transcription factor, upregulating genes that mediate cell cycle arrest and the intrinsic apoptotic pathway.

The system-level physiological consequence of this dual-target modulation is the suppression of cellular proliferation and the induction of programmed cell death across targeted tissues.

Dosage and Administration Information

Official Administration Guidelines

Aniprazol, a fixed-dose combination anthelmintic, is intended for oral use and is administered according to a weight-based dosing principle. The instructions for its use detail the required components, frequency, and specific age constraints, ensuring its application follows the established drug profile.

Instruction Classification	Official Use Principle
Route of Administration	The product must be administered exclusively for oral use in the available forms (tablet, suspension, or granules).
Standard Dosing Principle	The dose is calculated based on the animal’s body weight to deliver a fixed combination of 50 mg/kg of Fenbendazole and 5 mg/kg of Praziquantel.
Frequency Pattern	The regimen typically involves a single administration for treatment, though some instructions specify a three-day consecutive course depending on the specific parasitic target.

Contextual Administration and Constraints

The medicine is given with or without food, as fasting is not necessary prior to or following administration. For practical application, the dose can be administered either directly or readily mixed into the animal’s feed.

Certain constraints apply to use for certain populations. The product is not intended for use in puppies under 2 weeks of age or 0.5 kg in weight, nor in kittens less than 8 weeks of age. Furthermore, the medicine can be used in pregnant bitches during the last third of pregnancy, provided that the specified dose for the animal is not exceeded.

This structure dictates a standardized oral delivery and precise dosage calculation, confining use to the specific population parameters defined for this formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aniprazol

Evidence for Use in Mixed Nematode and Cestode Infections

The primary research for the Aniprazol combination (Fenbendazole and Praziquantel) was evaluated in the context of mixed infections involving both roundworms (nematodes) and tapeworms (cestodes). This research included controlled field efficacy trials, which studies explored how the medicine was evaluated in naturally infected populations, such as dogs and cats.

The studies focused on parasite clearance endpoints, along with monitoring outcomes related to physiological strain. Researchers primarily measured the reduction in fecal egg counts (FECR) and the conversion of an infected animal to a negative status following treatment. Findings describe patterns observed in the studies where measurements of reduced quantification of parasite eggs were reported after the administration of the combination drug. The regulatory evidence describes the consistency of these patterns, providing data for submission to health authorities.

Long-Term Studies and Duration of Effect

The question of how long the observed effects last has been examined by researchers. While core efficacy is typically measured in the short term (7–14 days), some protocols have included intermediate monitoring of parasite recurrence, with follow-up extending up to 90 days.

This longer-term observation contributes to the broader evidence landscape. However, long-term effects are not fully established beyond these intermediate follow-up durations. There is limited information for long-term outcomes regarding the durability of parasite clearance and the rates of infection recurrence over the entire lifespan of the host animal.

Key Limitations and Areas of Research Uncertainty

Overall, while the combination is well-established, evidence quality varies across studies. A significant limitation is that sample sizes were modest in many published reports. This means results apply only to the populations studied and not necessarily to diverse geographical and environmental settings. Furthermore, follow-up durations were limited in many primary efficacy studies, meaning the consequences of the treatment in terms of long-term effects are not fully established.

Key Studies & References Summary of Product Characteristics (SPC) for Anthelmintic Combination Drug (Fenbendazole/Praziquantel) - HPRA

Frequently Asked Questions (FAQ)

Common questions about Aniprazol (FAQ)

Q: Is Aniprazol the same type of medicine as [similar common drug name]?

According to official product information, Aniprazol is a fixed-dose combination containing two distinct types of antiparasitic medicines. These are Fenbendazole, which is a benzimidazole derivative, and Praziquantel, a pyrazinoisoquinoline derivative. This combination is strategically used to target a broad spectrum of parasites in the target species.

Q: How quickly should I expect Aniprazol to start working?

Official data indicates that one of the active ingredients, Praziquantel, is rapidly absorbed, typically reaching maximum concentration in approximately one hour. While the onset of antiparasitic action generally begins within one to two days, the visible clinical resolution of the infection may require the full treatment course.

Q: Can Aniprazol be taken by people with kidney issues?

Aniprazol is an approved veterinary medicine, which means it is intended for use only in dogs and cats and is not for human use. For the safety of the animals it is intended for, regulatory documents advise caution when considering use in animals with pre-existing kidney (renal) impairment.

Q: Are there long-term safety studies on Aniprazol?

Regulatory submissions include data from various toxicology studies, such as repeated-dose and generational studies, to establish the safety profile. However, long-term safety monitoring beyond these specific study durations is generally not established in the official summary documents for the lifespan of the host animal.

Q: What are the signs of a severe allergic reaction to Aniprazol?

Official veterinary guidance indicates that signs of a severe allergic reaction, or hypersensitivity, in the target species (dogs/cats) can include hives, facial swelling, difficulty breathing, or collapse. If these signs are observed, immediate veterinary attention is necessary.

Q: What common supplements might interact with Aniprazol?

The active ingredients are metabolized by a process known as the cytochrome P450 enzyme system in the liver. Products or supplements that inhibit or induce this system may alter the drug’s level in the body. For this reason, official information notes a restriction regarding the concomitant use of certain herbal supplements, such as St. John's Wort, due to its potential to reduce the drug's effectiveness.

Q: Is it possible for Aniprazol to stop working over time?

Anthelmintic resistance to the active ingredient Fenbendazole is a phenomenon that has been documented in certain parasite species. Due to this risk, the drug is recommended to be administered according to veterinary instructions to help mitigate the potential for parasites developing resistance.

Q: Is there a link between Aniprazol and liver problems?

Official safety data advises caution when considering use in animals that have pre-existing hepatic (liver) impairment. Furthermore, toxicology studies at high doses have noted certain effects on the liver, although the drug is generally well-tolerated at therapeutic doses.

Q: Can Aniprazol affect my heart rate?

Regulatory documents advise avoiding co-administration with other agents known to prolong the QTc interval. This restriction reflects a potential cardiac consideration related to the drug's metabolic profile, and it is a key consideration in the official drug interaction landscape.

Q: Can Aniprazol cause changes in mood?

Adverse events related to the nervous system, such as crying or restlessness, have been noted in association with doses that exceeded the recommended therapeutic level. Mood changes are not typically listed as a common or expected side effect at the prescribed dose.

Q: What happens if I forget to take my Aniprazol dose?

Official veterinary guidance indicates that re-treatment or further administration may be necessary if a scheduled dose is missed. Consultation with the prescribing veterinarian is the protocol for guidance on how to proceed, as they can assess the situation based on the specific treatment plan.

Q: Will Aniprazol affect my ability to drive or operate machinery?

Aniprazol is an approved veterinary medicine, which means it is intended for use only in dogs and cats and is not for human use. The regulatory information and safety data provided relate exclusively to the use in the target animal species.

Q: How long does Aniprazol stay in your system?

Pharmacokinetic data from regulatory studies in dogs indicate that the drug is eliminated relatively quickly. The elimination half-life for Praziquantel is approximately 3.5 hours, and the half-life for Fenbendazole and its active metabolite is approximately 5 hours.

Q: Is Aniprazol considered a controlled substance?

While Aniprazol is classified as a veterinary medicinal product subject to prescription (POM-V) in many regions, it is not designated as a federally controlled substance in the major regulatory jurisdictions.

Q: Can Aniprazol be used by children?

Aniprazol is an approved veterinary medicine, which means it is intended for use only in dogs and cats and is not for human use. The regulatory documentation and safety profile are specific to its use in the target animal species.

Q: Can I take Aniprazol if I have high blood pressure?

Q: Has Aniprazol been approved in countries outside the US?

Yes, Aniprazol (or similar combinations of the active ingredients) has received marketing authorization from multiple regulatory bodies globally. These include the European Medicines Agency (EMA), the UK's VMD (via the HPRA), and the US FDA Center for Veterinary Medicine.

Q: What is the purpose of the black box warning (if one exists) on Aniprazol?

A Black Box Warning is a regulatory requirement for certain medications with severe risks. Based on the official product summaries, no Black Box Warning is required or listed on the Summary of Product Characteristics (SmPC) for this veterinary medicine.

Q: Why is Aniprazol sometimes used for conditions other than its main purpose?

The primary indication is for the treatment of mixed nematode and cestode infections. However, some official product labels also include use as an aid in the control of certain parasites like Giardia protozoa in dogs and Aelurostrongylus abstrusus lungworm in cats.

Q: Does Aniprazol affect birth control pills?

Q: Can Aniprazol make anxiety worse for some people?

Q: What if Aniprazol doesn't seem to be helping my condition?

Official guidance states that if the animal's signs of illness worsen or do not improve, consultation with the prescribing veterinarian is necessary. They may recommend follow-up tests, such as fecal egg counts, to evaluate the efficacy of the treatment.

Q: What happens if I accidentally take a double dose of Aniprazol?

Official regulatory data on overdose indicates that both active ingredients are generally very well tolerated. After a severe overdose, occasional, non-serious effects such as vomiting and transient diarrhea may be reported in the animal being treated.

How should Aniprazol be stored and disposed of?

The storage and disposal of Aniprazol are defined by regulatory labeling to ensure product stability and prevent environmental contamination.

Official Storage Conditions

Storage Classification	Requirement
Storage Environment	Does not require any special storage conditions.
Stability	Shelf-life of the product as packaged for sale is 3 years.
Packaging Rule	Keep in the original container/packaging.
Child Protection	Must be kept out of the sight and reach of children.

Disposal Requirements

Official disposal instructions strictly state that the unused veterinary medicinal product or waste material must not be disposed of via wastewater or household waste. Disposal must utilize designated take-back schemes or national collection systems in accordance with local requirements.

Aniprazol